Inside information: Rob Kolkman appointed President and CEO of Sanoma as of 1 January 2024
Sanoma Corporation, Inside information, 20 November 2023 at 14:31 EET
Inside information: Rob Kolkman appointed President and CEO of Sanoma as of 1 January 2024
Sanoma’s Board of Directors has appointed Rob Kolkman President and CEO of Sanoma Corporation as of 1 January 2024. Rob succeeds Susan Duinhoven, who will continue as executive advisor to the company until the end of March 2024 to support a solid transition to the new CEO and assist in strategic projects.
"Rob is an experienced and engaging growth leader. During Rob’s almost four years at the helm of Sanoma Learning, net sales of Learning have doubled and its contribution of Sanoma’s operational earnings increased to approx. 80%. Rob knows Sanoma’s business and people well and has a clear view of how to continue executing and developing the strategy of future profitable growth, together with experienced leadership teams in both businesses. Both Learning and Media Finland have leading positions in their industries and a positive impact on the lives of millions of people every day, providing Sanoma a solid base forward. On behalf of the whole Board, I wish Rob the best of success in his new role," says Pekka Ala-Pietilä, Chair of the Board of Directors.
“I am honoured and excited to become the President and CEO of Sanoma. We have two strong businesses, both with good positions in their markets and clear strategies. I am looking forward to working together with our great team to further strengthen our position in European K12 learning services, to deliver on our key initiatives, including Program Solar, and to continue the successful digital transformation in our media business. I would like to express my appreciation to the Sanoma Board for the trust they have placed in me,” says Rob Kolkman, incoming President and CEO.
Rob Kolkman has worked with Sanoma and been a member of the Executive Management Team since 2019. First he worked as the CEO of Sanoma Media Netherlands until the divestment of the SBU in April 2020, and has since then worked as the CEO of Sanoma Learning. Prior to Sanoma, Rob worked in several executive roles at RELX Group for 15 years being based in the Netherlands, UK and Australia. His latest position at RELX was the Group Managing Director of Reed Business Information in London. Earlier, he has also worked in managerial roles at BPP Professional Education in the Netherlands. Rob was born in 1972 and he is a Dutch citizen residing in Finland since 2020. He holds an MBA from NIMBAS, Bradford – Graduate School of Management and Master of Economics (Accountancy) from VU Amsterdam.
In his role as President and CEO of Sanoma Corporation, Rob will continue to lead Sanoma Learning together with a recently further strengthened Learning leadership team.
Investors: Kaisa Uurasmaa, Head of Investor Relations and Sustainability, tel. +358 40 560 5601
Finnish media: Marcus Wiklund, Director, Public Affairs, tel. +358 400 603147
International media: Christel Lammertink, Communication Director, Sanoma Learning, tel. +31 6 5715 3456
Sanoma is an innovative and agile learning and media company impacting the lives of millions every day. Our Sustainability Strategy is designed to maximise our positive ‘brainprint’ on society and to minimise our environmental footprint. We are committed to the UN Sustainable Development Goals and signatory to the UN Global Compact.
Our learning products and services enable teachers to develop the talents of every child to reach their full potential. We offer printed and digital learning content as well as digital learning and teaching platforms for primary, secondary and vocational education, and want to grow our business.
Our Finnish media provide independent journalism and engaging entertainment also for generations to come. Our unique cross-media position offers the widest reach and tailored marketing solutions for our business partners.
Today, we operate in twelve European countries and employ more than 5,000 professionals. In 2022, our net sales amounted to approx. 1.3bn€ and our operational EBIT margin excl. PPA was 14.6%. Sanoma shares are listed on Nasdaq Helsinki. More information is available at sanoma.com.
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Karolinska Development's portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates6.12.2023 12:38:48 CET | Press release
STOCKHOLM, SWEDEN, December 6, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that the portfolio company OssDsign expects revenues for the fourth quarter of 2023 to exceed market expectations. Preliminary total revenues for the period October - November amount to SEK 25.2 million, mainly attributable to a continued strong market performance of the company's orthobiologic franchise and some extraordinary orders from a large hospital system. According to preliminary and unaudited data, sales of OssDsign Catalyst amounted to SEK 18.8 million during the period of October – November 2023, whereas OssDsign Cranial recorded sales of SEK 6.4 million. A complete financial statement for the fourth quarter will be presented in OssDsign’s year-end report for 2023, to be published on February 6, 2024. "OssDsign continues its strong growth journey, and we are confident that the company's new strategic direction to fully focus the business on its high-margin orthobiologic franchis
Karolinska Developments portföljbolag OssDsign bedömer att intäkterna för fjärde kvartalet kommer att överträffa marknadens förväntningar6.12.2023 12:38:48 CET | Pressemelding
STOCKHOLM, SVERIGE 6 december 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget OssDsign bedömer att intäkterna för det fjärde kvartalet 2023 kommer överträffa marknadens förväntningar. De preliminära totala intäkterna för perioden oktober – november uppgår till 25,2 MSEK, främst till följd av en fortsatt stark marknadsutveckling för bolagets ortobiologiprodukter och ett antal större ordrar från ett stort sjukhusnätverk. Enligt preliminära och oreviderade försäljningsdata för perioden oktober – november 2023 uppnåddes intäkter om 18,8 miljoner kronor för OssDsign Catalyst, medan intäkterna för OssDsign Cranial uppgick till 6,4 miljoner kronor. En fullständig finansiell rapport för det fjärde kvartalet kommer att presenteras i OssDsigns bokslutskommuniké för 2023, som publiceras den 6 februari 2024. ”OssDsign fortsätter sin starka tillväxtresa och vi är övertygade om att bolagets nya strategiska inriktning för att fullt fokusera verksamheten på sina o
XPENG G9 Achieves a Five-Star 2023 Safety Rating from Euro NCAP6.12.2023 11:00:00 CET | Press release
The new XPENG G9, now on sale in Europe, received a five-star 2023 safety rating from Euro NCAPThis is XPENG's second five-star safety rating for an international model following the new P7 in October; and its first SUV obtained both Euro NCAP and C-NCAP five-star ratings AMSTERDAM, Dec. 06, 2023 (GLOBE NEWSWIRE) -- XPENG Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announces that the international model of their flagship electric SUV, XPENG G9, has received a five-star 2023 safety rating from Euro NCAP. Euro NCAP's five-star safety rating system aims to help consumers, their families and businesses compare vehicles more easily and identify the safest choice for their needs. The tests, which replicate real-life road danger scenarios, represent the European gold standard for comprehensive automotive safety testing. The rating recognises the XPENG G9's advanced body structure and comprehensive passive s
AS Tallink Grupp: Managers’ Transactions6.12.2023 11:00:00 CET | Press release
Person subject to the notification requirement Name: AS Infortar Position: Closely associated person (X) Legal person Person Discharging Managerial Responsibilities in Issuer Name: Hanschmidt, Ain Position: Member of the Supervisory Board Name: Pant, Eve Position: Member of the Supervisory Board Issuer: AS Tallink Grupp LEI: 529900QRMWAKKR3L9W75 Notification type: Initial Notification _____________________________________ Transaction date: 04.12.2023 Venue: Nasdaq OMX Tallinn Instrument type: Share ISIN: EE3100004466 Nature of the transaction: Acquisition Transaction details: (1): Volume: 105,178; Unit price: 0.68 EUR Aggregated transactions: (2): Volume: 105,178; Volume weighted average price: 0.68 EUR Anneli Simm Investor Relations Manager AS Tallink Grupp Sadama 5 10111 Tallinn E-mail Anneli.firstname.lastname@example.org
CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy6.12.2023 11:00:00 CET | Press release
ZÜRICH, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy (GA). Licensed to Boehringer Ingelheim, BI 771716 is a highly specific antibody fragment of reduced size, enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology. The Phase 1 study (NCT06006585) is evaluating the safety, tolerability and pharmacokinetics of intravitreal single rising doses and multiple doses of BI 771716 as a potential treatment for GA. GA is a chronic and progressive, irreversible retinal disease that occurs in people with late-stage dry age-related macular degeneration (AMD) impacting the ability to see. More than 5 million people worldwide suffer from GA, of which more than 40% are legally blind. GA worsens with age, affecting 1 in 29 people above the age of 75 and 1 in 4 people above 90. Consequently, risi